EAST HANOVER, N.J. — The Food and Drug Administration has approved Diovan as a treatment for reducing cardiovascular deaths in patients who are at high risk after suffering a heart attack.
The regulatory agency granted Novartis Pharm…
Novartis AG plans to combine its newer heart pill Tektuma with Diovan and says that it expects to bring the new therapy to market prior to the expiration of the patent for Diovan in 2012. Switzerland-based Novarti…
FDA APPROVES DIOVAN: Novartis Pharmaceuticals Corp. has announced that the Food and Drug Administration has approved Diovan (valsartan) for a new indication to reduce cardiovascular death in patients at high risk following a heart attack. As a result, the drug can now be prescribed in a broader range of heart-failure patients.
Related Results
DiovanDiovanDiovan dosesNew indication for diovanHill Holliday net…
